Faster global financial news!
British pharmaceutical giant GSK licenses cancer drug from China's Chimagen Biosciences in deal worth up to $750 million
GSK announced plans on Tuesday to acquire full global rights to a T-cell engager (TCE) from Chengdu-based Chimagen, targeting treatment for multiple myeloma, a type of blood cancer.
No AI analysis yet. Tap the "AI Analysis" button above to generate one now.
Source：SCMP商业 · Source Link
Disclaimer: This content reflects only the author’s personal views and does not constitute any investment or financial advice. If you discover any content that violates regulations,Click to Report
Previous: Iraqi PM Zaidi faces struggle to control armed factions after Saudi oil pipeline attack; senior source points to 'splinter' group
|
Next: On September 16, the three major A-share indices all fell during the morning session, while the STAR 50 index bucked the trend and rose by more than 1%; Hong Kong stocks opened higher but closed lower, with both the Hang Seng Index and the Hang Seng Tech Index posting declines.
24H Trending
-
1
Bitcoin vs. Ethereum: A Guide to the Strengths and Choices Between the Two Crypto Giants
-
2
BNB and Investment Banking Integration: Binance's Strategic Expansion into Traditional Financial Services
-
3
Cardano (ADA): Positioning and Outlook in the Future Financial System
-
4
What is MSQ Coin? MSquare Global Token Analysis and Trading Channels
-
5
BitShares (BTS) Coin: Exchange Platforms, Founder, and Core Mechanism Analysis
-
6
In-depth Analysis of ImmutableX (IMX) Social Media Influence
-
7
MDA Coin: Moeda Loyalty Points Project Analysis and Market Status
-
8
Analysis of Top 10 Cryptocurrencies by Market Cap on OKX Platform (as of October 30, 2025)
-
9
What is POPO Coin? Analyzing Multiple Meme Token Projects with the Same Name
-
10
Bitcoin Permanently Lost: The Truth Behind the $10 Billion Rumor and Actual Quantity Estimates
Markets Today
Recommended Reading
Hot Topics
Svmuu focuses on blockchain industry trends and cutting-edge cryptocurrency news, while also covering real-time market data and in-depth analysis of the Hong Kong, U.S., and foreign exchange markets. Here, you can not only access professional 24/7 news updates and accurate market data, but also utilize practical investment tools to help you capitalize on opportunities in both digital assets and traditional financial markets. Whether you are a blockchain enthusiast or an investor in Hong Kong, U.S., or foreign exchange markets, we provide efficient and timely information services to empower your investment decisions.
- User Agreement
- Privacy Policy
- Contact Us
- Business Partnerships
- Disclaimer
- Content Statement
- About Us
- Sitemap
Coming Soon!
